Dealmaking is picking up across the globe, with two large acquisitions leading the charge. London Stock Exchange Group (LSEG), the UK-based market operator and data provider, has agreed to buy credit-data firm Octus for $3.54 billion. At the same time, Swedish private equity firm EQT has struck a deal worth roughly €9.6 billion to acquire QIAGEN, a Dutch molecular-testing company. These moves, along with several smaller transactions, show that investors and companies are still willing to make big bets even as markets face uncertainty.
Why these deals matter
The common thread among many of these transactions is a focus on owning scarce assets and building businesses that are hard to replicate. For LSEG, the Octus acquisition adds proprietary credit information that can be bundled into its existing analytics subscriptions. The goal is to make LSEG's tools more embedded in clients' day-to-day workflows, especially as artificial intelligence reshapes how research and risk decisions are made. By integrating Octus's data, LSEG hopes to become a more essential part of how lenders and credit investors operate.
EQT's move for QIAGEN highlights the ongoing value of scaled testing platforms. Hospitals and laboratories tend to stick with trusted systems, which creates repeat revenue. QIAGEN's molecular testing technology is used in diagnostics and research, and its established customer base makes it an attractive target for a private equity firm looking for stable cash flows.
Smaller deals fill gaps
Beyond the headline transactions, several smaller moves are also notable. Italy's state-backed CDP Equity is buying an 8.9% stake in airport operator 2i Aeroporti, a move that reflects continued interest in infrastructure assets. UBS, the Swiss banking giant, has taken about a 4.8% stake in India's 360 One Wam by converting warrants, deepening its partnership with the wealth management firm. And Integrated Specialty Coverages, a US insurance company, has bought California wholesaler USASIA to expand its distribution network.
These deals, while smaller, show that dealmakers are active across different sectors and regions. From airports in Italy to financial services in India, investors are looking for opportunities to grow or consolidate their positions.
What it means for investors
For LSEG, the $3.54 billion price tag for Octus only makes sense if the company can turn that credit dataset into a broader, must-have workflow for lenders and credit investors. Data businesses often win through cross-selling: once a customer integrates the information into pricing models, risk systems, and reporting, switching providers becomes costly in both time and compliance effort. This tends to support renewals and creates room to sell add-on analytics, which usually carry higher incremental margins than transaction-led revenue.
The upshot is that LSEG's valuation could become less sensitive to trading volumes and more tied to whether data clients keep renewing and expanding their subscriptions—a metric often described as net revenue retention. For investors, this means LSEG's earnings may become more predictable and less cyclical, which could support a higher valuation multiple over time.
For EQT, the QIAGEN deal is a large bet on healthcare. Private equity firms often look for companies with strong market positions and recurring revenue, and QIAGEN fits that profile. However, such large deals also carry risks, including integration challenges and potential regulatory hurdles. Investors should watch how EQT plans to finance the acquisition and whether it can improve QIAGEN's growth prospects.
For everyday investors, these deals are a reminder that M&A activity can be a signal of confidence in certain sectors. Data and healthcare are seen as areas with long-term growth potential, and companies are willing to pay premium prices to gain a foothold. However, it's important to remember that not all deals succeed. Integration risks, cultural clashes, and changing market conditions can all derail even the most promising acquisitions.
Looking ahead
Investors will be watching to see if these deals close and how they perform in the coming quarters. For LSEG, the focus will be on how quickly it can integrate Octus and start cross-selling its data products. For EQT, the question is whether it can improve QIAGEN's operational efficiency and drive growth. The smaller deals, meanwhile, may not move markets on their own, but they offer clues about where investors see value.
As always, it's wise to keep an eye on the broader economic backdrop. Interest rates, inflation, and geopolitical tensions can all influence dealmaking activity. But for now, the message from the market is clear: dealmakers are busy, and they're willing to pay up for assets they believe will be valuable in the long run.
